DALLAS, November 21, 2014 /PRNewswire/ --
ReportsnReports.com adds Global Oncology Biosimilars Market 2014-2018 industry research report of 71 pages to the life science intelligence collection of its online library. According to this report, global oncology biosimilars market is forecast to grow at a CAGR of 29.87 percent over the period 2013-2018. Complete report is available at http://www.reportsnreports.com/reports/317863-global-oncology-biosimilars-market-2014-2018.html .
This report covers the present scenario and the growth prospects of the Global Oncology Biosimilars market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales biosimilars used in cancer treatment. Biosimilars are follow-on versions of biological medicines that are developed after the expiry of the patent protection on the original product. Biosimilar medicines have a mechanism of action that is similar to that of the original biological medicines. Though biosimilars have many similarities to the innovator product, they are not an exact copy of the reference biopharmaceutical product. Currently, biosimilars are being incorporated into oncology treatment practices. The biosimilars used in oncology in the supportive care setting are known as oncology biosimilars.
The Global Oncology Biosimilars Market 2014-2018 research report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Oncology Biosimilars market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Increased numbers of patent expirations are driving the oncology biosimilars market growth. Since biosimilars are follow-on versions of original biological medicines and can be made only after the patent protection of the original product expires, these expirations open up opportunities for many biosimilars companies to enter the market. One of the major challenges faced by the industry is the risks related to drug failure. Outsourcing of biosimilars manufacturing is a trend observed which may help push profitability in the industry. Contract research manufacturers and CROs in countries like India and China are set to benefit because of this trend, which creates a win-win situation for all stakeholders of the industry.
Companies like Biocon, Celltrion, Dr. Reddy's Laboratories, Hospira, Mylan, Sandoz, 3SBio, Abbvie, AstraZeneca, BioXpress Therapeutics, Boehringer Ingelheim, Coherus Biosciences, Intas Pharmaceuticals, Merck Serono, Pfizer and Wockhardt are discussed in this research on oncology biosimilars market available for purchase at http://www.reportsnreports.com/Purchase.aspx?name=317863 .
List of Exhibits provided in global oncology biosimilars market 2014-2018 research report includes:
Market Research Methodology
Global Oncology Biosimilars Market 2013-2018 (US$ million)
Oncology Biosimilar Drug Segmentation by Application
Global Oncology Biosimilars Market by Geographical Segmentation 2013
Biocon: Business Segmentation by Revenue 2014
Biocon: Business Segmentation by Revenue 2013 and 2014 (US$ million)
Celltrion: Product Segmentation 2013
Global Oncology Biosimilars market: Business Segmentation by Revenue 2014
Global Oncology Biosimilars market: Business Segmentation by Revenue 2013 and 2014 (US$ billion)
Dr. Reddy's Laboratories: Geographical Segmentation by Revenue 2014
Global Oncology Biosimilars market: Business Segmentation by Revenue 2013
Global Oncology Biosimilars market: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Global Oncology Biosimilars market: Geographical Segmentation by Revenue 2013
Global Oncology Biosimilars market: Business Segmentation by Revenue 2013
Global Oncology Biosimilars market: Business Segmentation by Revenue 2011-2013 (US$ billion)
Global Oncology Biosimilars market: Geographical Segmentation by Revenue 2013
Sandoz: Product Segmentation 2013
Another research on Personalized Medicine in Oncology Partnering Terms and Agreement provides a detailed understanding and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Available contracts are listed by Headline value, Stage of development at signing, Deal component type, Specific therapy target and Specific technology target. Each deal title links via Weblink to online deal records of actual personalized medicine in oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
There are some concerns around biosimilar use, for example with physicians worried about how similar certain drugs are and whether they can safely be used in particular patient populations such as transplant, due to the potential for variance in efficacy and tolerability. Despite this, it is expected that the biosimilar market will continue to experience significant growth in the next five to ten years, being driven by the extensive pipeline and the number of companies becoming involved in this area including some big pharma who are seizing the opportunity to develop biosimilar versions of competitor products in order to ensure they are able to compete at all levels. The Biosimilars - Biosimilars on the cusp of a new era market research report provides an in-depth insight into recent biosimilar regulatory developments including a comparison of the processes used in different markets and the guidance being implemented.
This report helps assess the biosimilars pipeline including where development is currently focused and the potential impact new biosimilars will have on the marketplace. It highlights industry opinions towards biosimilars and their expected impact in different therapy areas and how industry can meet the challenges being presented by biosimilar development and launches. In addition to providing an understanding about the key concerns around biosimilar development and use, including manufacturing concerns and issues around automatic substitution, this research also provides an overview of the key companies involved in the biosimilar market including an analysis of where the majority of biosimilar companies are located, the markets in which they operate and the future outlook .
Explore more reports on oncology market, biotechnology industry (http://www.reportsnreports.com/market-research/biotechnology/ ) and the pharmaceuticals sector at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
About Us:
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas 75252
Tel: +1-888-391-5441 [email protected]
Connect With Us on:
Facebook: https: //http://www.facebook.com/pages/ReportsnReports/191441427571689
LinkedIn: http://www.linkedin.com/company/reportsnreports
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
Pinterest: http://www.pinterest.com/comeonseo/reportsnreports/
RSS/Feeds: http: //http://www.reportsnreports.com/feed/l-latestreports.xml
SOURCE ReportsnReports
ReportsnReports.com adds Global Oncology Biosimilars Market 2014-2018 industry research report of 71 pages to the life science intelligence collection of its online library. According to this report, global oncology biosimilars market is forecast to grow at a CAGR of 29.87 percent over the period 2013-2018. Complete report is available at http://www.reportsnreports.com/reports/317863-global-oncology-biosimilars-market-2014-2018.html .
Advertisement
This report covers the present scenario and the growth prospects of the Global Oncology Biosimilars market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales biosimilars used in cancer treatment. Biosimilars are follow-on versions of biological medicines that are developed after the expiry of the patent protection on the original product. Biosimilar medicines have a mechanism of action that is similar to that of the original biological medicines. Though biosimilars have many similarities to the innovator product, they are not an exact copy of the reference biopharmaceutical product. Currently, biosimilars are being incorporated into oncology treatment practices. The biosimilars used in oncology in the supportive care setting are known as oncology biosimilars.
Advertisement
The Global Oncology Biosimilars Market 2014-2018 research report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Oncology Biosimilars market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Increased numbers of patent expirations are driving the oncology biosimilars market growth. Since biosimilars are follow-on versions of original biological medicines and can be made only after the patent protection of the original product expires, these expirations open up opportunities for many biosimilars companies to enter the market. One of the major challenges faced by the industry is the risks related to drug failure. Outsourcing of biosimilars manufacturing is a trend observed which may help push profitability in the industry. Contract research manufacturers and CROs in countries like India and China are set to benefit because of this trend, which creates a win-win situation for all stakeholders of the industry.
Companies like Biocon, Celltrion, Dr. Reddy's Laboratories, Hospira, Mylan, Sandoz, 3SBio, Abbvie, AstraZeneca, BioXpress Therapeutics, Boehringer Ingelheim, Coherus Biosciences, Intas Pharmaceuticals, Merck Serono, Pfizer and Wockhardt are discussed in this research on oncology biosimilars market available for purchase at http://www.reportsnreports.com/Purchase.aspx?name=317863 .
List of Exhibits provided in global oncology biosimilars market 2014-2018 research report includes:
Market Research Methodology
Global Oncology Biosimilars Market 2013-2018 (US$ million)
Oncology Biosimilar Drug Segmentation by Application
Global Oncology Biosimilars Market by Geographical Segmentation 2013
Biocon: Business Segmentation by Revenue 2014
Biocon: Business Segmentation by Revenue 2013 and 2014 (US$ million)
Celltrion: Product Segmentation 2013
Global Oncology Biosimilars market: Business Segmentation by Revenue 2014
Global Oncology Biosimilars market: Business Segmentation by Revenue 2013 and 2014 (US$ billion)
Dr. Reddy's Laboratories: Geographical Segmentation by Revenue 2014
Global Oncology Biosimilars market: Business Segmentation by Revenue 2013
Global Oncology Biosimilars market: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Global Oncology Biosimilars market: Geographical Segmentation by Revenue 2013
Global Oncology Biosimilars market: Business Segmentation by Revenue 2013
Global Oncology Biosimilars market: Business Segmentation by Revenue 2011-2013 (US$ billion)
Global Oncology Biosimilars market: Geographical Segmentation by Revenue 2013
Sandoz: Product Segmentation 2013
Another research on Personalized Medicine in Oncology Partnering Terms and Agreement provides a detailed understanding and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Available contracts are listed by Headline value, Stage of development at signing, Deal component type, Specific therapy target and Specific technology target. Each deal title links via Weblink to online deal records of actual personalized medicine in oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
There are some concerns around biosimilar use, for example with physicians worried about how similar certain drugs are and whether they can safely be used in particular patient populations such as transplant, due to the potential for variance in efficacy and tolerability. Despite this, it is expected that the biosimilar market will continue to experience significant growth in the next five to ten years, being driven by the extensive pipeline and the number of companies becoming involved in this area including some big pharma who are seizing the opportunity to develop biosimilar versions of competitor products in order to ensure they are able to compete at all levels. The Biosimilars - Biosimilars on the cusp of a new era market research report provides an in-depth insight into recent biosimilar regulatory developments including a comparison of the processes used in different markets and the guidance being implemented.
This report helps assess the biosimilars pipeline including where development is currently focused and the potential impact new biosimilars will have on the marketplace. It highlights industry opinions towards biosimilars and their expected impact in different therapy areas and how industry can meet the challenges being presented by biosimilar development and launches. In addition to providing an understanding about the key concerns around biosimilar development and use, including manufacturing concerns and issues around automatic substitution, this research also provides an overview of the key companies involved in the biosimilar market including an analysis of where the majority of biosimilar companies are located, the markets in which they operate and the future outlook .
Explore more reports on oncology market, biotechnology industry (http://www.reportsnreports.com/market-research/biotechnology/ ) and the pharmaceuticals sector at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
About Us:
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas 75252
Tel: +1-888-391-5441 [email protected]
Connect With Us on:
Facebook: https: //http://www.facebook.com/pages/ReportsnReports/191441427571689
LinkedIn: http://www.linkedin.com/company/reportsnreports
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
Pinterest: http://www.pinterest.com/comeonseo/reportsnreports/
RSS/Feeds: http: //http://www.reportsnreports.com/feed/l-latestreports.xml
SOURCE ReportsnReports
